Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Equity Ratio (2016 - 2025)

Aptevo Therapeutics' Equity Ratio history spans 11 years, with the latest figure at 0.64 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 120.76% year-over-year to 0.64; the TTM value through Sep 2025 reached 0.64, up 120.76%, while the annual FY2024 figure was 0.3, 38.01% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.64 at Aptevo Therapeutics, up from 0.42 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.67 in Q1 2023 and bottomed at 0.18 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.35 (2024), against an average of 0.33.
  • The largest YoY upside for Equity Ratio was 2345.22% in 2022 against a maximum downside of 185.24% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.02 in 2021, then skyrocketed by 2345.22% to 0.53 in 2022, then dropped by 6.35% to 0.49 in 2023, then crashed by 38.01% to 0.3 in 2024, then skyrocketed by 111.24% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Equity Ratio are 0.64 (Q3 2025), 0.42 (Q2 2025), and 0.18 (Q1 2025).